Latest News
Second Parkinson’s Therapy Funded by The Michael J. Fox Foundation Receives FDA Approval and Advances to Market

May 22nd, 2020

NEW YORK (May 22, 2020) — The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announces a milestone in the Foundation’s impact on the Parkinson’s disease (PD) therapeutic landscape. On May 21, 2020, the U.S. Food and Drug Administration approved Kynmobi from Sunovion Pharmaceuticals Inc. This new therapy — which treats “off” time, when PD symptoms are not well controlled with oral medication — marks the second regulatory...

Read more

Dignity (Latest Edition)

Read the book online